3 compound preparations through consistent evaluation from East China Medicine, Fuyuan Medicine...

On September 16th, the official website of the Drug Administration showed that three compound preparations were evaluated by consistency, namely, the pyridoxine metformin tablets of East China Pharmaceuticals, the potassium amoxicillinclavin tablets of North China Pharmaceuticals and the potassium chloraten hydrochloride tablets of Fuyuan Pharmaceuticals.
, the 12 are the first to pass a consistency rating.
is a compound of pyridoxine and metformin tablets used to treat type 2 diabetes.
combined with metformin is one of the basic treatment options for type 2 diabetes recommended by authoritative guidelines at home and abroad, with extensive clinical experience and extensive evidence-based medical evidence.
two drug action mechanisms complement each other, improve insulin sensitivity, effectively reduce sugar at the same time positively regulate blood lipids, improve patients' blood pressure, reduce cardiovascular risk, and bring multiple benefits of treatment.
currently only Deyuan Pharmaceuticals and East China Pharmaceuticals' Pyridoxine metformin tablets have been approved for market, the former has been the first to pass a consistent evaluation on August 10.
Chinese Pharmaceutical Society Sample Hospital Data (CPA Data) shows that the total sales of domestic Pythyl glycodone metformin sample hospitals in 2019 were approximately 90.16 million yuan.
of chlorosatan potassium hydrochlorochlorophenidate tablets chlorosatan potassium hydrochlorophenidate tablets are a compound preparation of chlorosatan and hydrochlorochlorophenidate for the treatment of hypertension.
was approved by the FDA as early as 1995, with peak sales of more than $3.5 billion and sales of $442 million in 2019.
domestic production and sale of chlorosatan potassium hydrochlorochlorine tablets have 6 manufacturers, Fuyuan Pharmaceuticals is the first manufacturer through a consistent evaluation.
addition to this, Lepu Pharmaceuticals has submitted a consistent evaluation application in October 2019.
Amoxilin kravytate potassium tablets Amoxilin Kravy acid tablets have a broad-spectrum antibacterial effect and can be used to treat various infections caused by the production of β-endamidease and resistance to amosillin-resistant Glocylin-negative bacteria.
include: upper and lower respiratory tract infections, otitis otitis, acute sinusitis, nephritis and lower urethritis, and skin and soft tissue infections.
more than 10 potassium amasilin kravytate tablets produced and sold in China, North China Pharmaceuticals was the first manufacturer to pass a consistent evaluation of the drug.
addition to North China Pharmaceuticals, four companies submitted applications for consistency evaluation, including Synth Pharmaceuticals (Category 4), Lu Nambet, Xiangbei Wilman Pharmaceuticals and Hong Kong Australia and the United States.
.